Live prices from 0 SA suppliers, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
We haven't found any suppliers listing this peptide yet. Check back soon as we update our database regularly.
We haven't found any suppliers listing this peptide yet. Check back soon as we update our database regularly.
More ways to compare Survodutide
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
29-amino acid peptide
14.9% mean weight loss at 46 weeks (4.8mg); 55% achieved ≥15% reduction.
Superior to semaglutide: -8.7% vs -5.3% at 16 weeks.
Dual mechanism addresses both energy intake and expenditure.
62% achieved MASH improvement without fibrosis worsening at 4.8mg.
63-67% achieved ≥30% liver fat reduction.
HbA1c reduction up to -1.6% at highest doses.
Subcutaneous injection to abdomen (2+ inches from navel), upper thigh, or upper arm. Any time of day, with or without food.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Obesity - Conservative Start | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | SubQ |
| Obesity - Standard Protocol | 3.6-6.0mg | Once weekly | SubQ |
| MASH Treatment | 2.4-4.8mg | Once weekly | SubQ |
| Type 2 Diabetes | 0.3-2.7mg | Once weekly | SubQ |
Both GLP-1 agonists; combining risks excessive activation and GI side effects.
Demonstrated together in Phase 2 diabetes trials.
No known interactions; allowed in Phase 3 with monitoring.
Hypoglycemia risk; consider dose reduction.
May require insulin dose reduction due to improved glycemic control.
Take 1+ hour before survodutide due to delayed gastric emptying.
Risk of excessive glucagon receptor activation.
Possible nausea, reduced appetite (most common during escalation)
Initial weight loss begins; improved satiety between meals
Progressive weight loss; potential energy level improvements
Approaching steady-state; more consistent effects
Sustained weight loss; average 15-19% by week 46
387 participants; BMI ≥27 kg/m²; 46 weeks. 14.9% mean weight loss at 4.8mg; 83% achieved ≥5%, 69% achieved ≥10%, 55% achieved ≥15%.
293 participants with biopsy-confirmed MASH; 48 weeks. MASH improvement: 62% (4.8mg) vs 14% placebo; 63-67% achieved ≥30% liver fat reduction.
Head-to-head vs semaglutide 1.0mg; 16 weeks. Survodutide -8.7% weight loss vs semaglutide -5.3%; HbA1c reduction up to -1.6%.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.